glp-1 agonist and dpp-4 inhibitor Comparison of receptor agonists inhibitors DPP-4 Inhibitors and the Quest

In healthy bodies, these two hormones sort of work in concert to keep blood sugar at a healthy level

The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus

The trial focused on: Percentage of body weight lost Changes in blood sugar levels Shifts in blood pressure Tolerability at different doses, including the highest dose Safety over a longer treatment period This approach helped determine how the Eli Lilly weight-loss study compares to earlier GLP-1 research

Acknowledgements Funding This review and the article processing charges were funded by Eli Lilly Australia

Wang XW, Zhang FX, Yang F, Ding ZF, Agarwal N, Guo ZK, Mehta JL